NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 149.78 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 102.37K shares.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 47.41K shares.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 116.35K shares.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 180.31K shares, a 34.36% decline from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 274.68K shares, a 86.48% decline from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 2.03M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 102.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 149.78K shares 10-Q · filed 2026-08-05 | 266.13K shares derived: sum of 3 quarters · filed 2026-08-05 | |
| 2026-03-31 | 47.41K shares 10-Q · filed 2026-05-07 | 163.76K shares derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | 116.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | 180.31K shares 10-K · filed 2026-02-18 | ||
| 2025-09-30 | 63.96K shares 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | 274.68K shares 10-K · filed 2025-02-26 | |||
| 2023-12-31 | 2.03M shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |